Drugs / FOSFOCREATINE
FOSFOCREATINE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03138681 | May 2017 → Apr 2019 | major depressive disorder | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT06503016 | Oct 2024 → Apr 2026 overdue | bronchial disorder, cardiac arrest, heart failure, hypotensive disorder +1 | Vita-Salute San Raffaele University | Recruiting | No outcome recorded |
| Phase 3 | NCT02757443 | Jun 2016 → Apr 2021 | cardiac valvular defect | Meshalkin Research Institute of Pathology of Circulation | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05431413 Comparator | Jan 2020 → Dec 2025 | depressive disorder | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOSFOCREATINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1204644 ↗ |
| Known as | Creatine phosphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1204644 ↗ |
| Known as | Creatine-p | ChEMBL registry synonym — accepted as the source's own label CHEMBL1204644 ↗ |
| Known as | PCr | “Previous studies have revealed that the decrease of bio-energetic metabolism may contribute to the occurrence of depression, while our team has found adenosine triphosphate...” PMID 30626424 ↗ Jan 20191“2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)” NCT02757443 ↗ |
| Known as | Phosphagen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1204644 ↗ |
| Known as | Phosphocreatine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02757443 ↗ |
| Modality | Small molecule | — CHEMBL1204644 ↗ |
| Route | Intravenous | “during 30 min intravenous (IV)” NCT02757443 ↗ |